BIVV020 (SAR445088) n Prevention and Treatment of Antibody-mediated Rejection (AMR)

Inclusion Criteria:

-Participant intended to receive SOC therapy per Investigator's judgment and local practice.

Cohort A: Participants with chronic kidney disease who will receive a kidney transplant from a living or deceased donor.

Cohort B: Participants who are kidney transplant recipients diagnosed with active AMR.

• BMI ≤ 40 kg/m2.

• Contraceptive use by women during the treatment period, and for at least 49 weeksafter the last administration of IMP (BIVV020 + SOC arm participant) or lasttreatment period visit (SOC arm participant).

• Contraceptive use by men during the treatment period, and for at least 49 weeksafter the last administration of IMP (BIVV020 + SOC arm participant) or lasttreatment period visit (SOC arm participant).

Exclusion Criteria:

• Participants who are ABO incompatible with their donors.

• Participants with known active ongoing infection as per below:

1. Positive HIV.

2. Positive HBV.

3. HCV with detectable HCV RNA.

4. Within 4 weeks of first study intervention: any serious infection, or anyactive bacterial infection, or any other infection which is clinicallysignificant in the option of the Investigator, unless it can be confirmed thatinfection was cleared at least 3 days prior to first study intervention.

• History of active tuberculosis (TB) regardless of treatment.

• Participants with clinical diagnosis of systemic lupus erythematosus (SLE).

• Prior treatment with complement system inhibitor within 5 times the half-life.

• Current enrollment in any other clinical study where the last investigational studytreatment administration was within 5 half-lives from study intervention initiation.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.